679405-87-9

Usage

Chemical compound

6-CHLORO-3-CHLOROMETHYL-4-METHOXYPYRIDAZINE

Molecular weight

209.06 g/mol

Structural features

Chloromethyl group at the 3-position, chloro group at the 6-position, methoxy group at the 4-position

Common uses

Intermediate in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds

Potential applications

Medicinal chemistry, drug development

Precautions

Handle with care in a controlled environment due to potential hazards and toxicity.

Upstream product

• 1830-54-2 3-oxopentanedioic acid dimethyl ester 
• 679405-85-7 6-chloro-4-methoxypyridazine-3-carboxylic acid methyl ester 
• 372118-01-9 4,6-dichloro-pyridazine-3-carboxylic acid methyl ester 
• 372118-00-8 4,6-dihydroxy-pyridazine-3-carboxylic acid methyl ester 
• 83878-89-1 2-diazo-3-oxo-pentanedioic acid dimethyl ester 
• 679405-86-8 (6-chloro-4-methoxypyridazin-3-yl)methanol 

Downstream Products

• 679405-22-2 6-Chloro-3-[2-(3-chloro-2,6-difluoro-phenyl)-imidazol-1-ylmethyl]-4-methoxy-pyridazine 
• 679405-25-5 1-{6-[2-(3-chloro-2,6-difluoro-phenyl)-imidazol-1-ylmethyl]-5-methoxy-pyridazin-3-yl}-ethanone 
• 679405-24-4 3-[2-(3-chloro-2,6-difluoro-phenyl)-imidazol-1-ylmethyl]-4-methoxy-6-thiazyl-pyridazine 

Relevant academic research and scientific papers

C5A RECEPTOR MODULATORS

The present invention relates to derivatives of formula (I) wherein ring A, X, Y, Z, R1, R2, R3 and R4 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as C5a receptor modulators.

Imidazol-1-ylmethyl pyridazine derivatives

The invention provides imidazol-1-ylmethyl pyridazine derivatives of the formula: 1 that bind to GABAA receptors. In the above formula, R1, R2 R3, R4, R5, R6 and Ar are defined herein. Such compounds may be used to modulate ligand binding to GABAA receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of central nervous system (CNS) disorders in humans, domesticated companion animals, and livestock animals. Compounds provided herein may be administered alone or in combination with one or more other CNS agents to potentiate the effects of the other CNS agent(s). Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for detecting GABAA receptors (e.g., receptor localization studies).